BioSpace News Archive

The company and Operation Warp Speed began distribution of the vaccine through McKesson, along with United Parcel Services and FedEx, over the weekend. The first vaccinations are expected today.

The FDA put a clinical hold on UniQure’s Phase III trial after a high-risk participant developed liver cancer.

Genentech, a Roche company, announced positive topline data from two identical Phase III trials of faricimab in diabetic macular edema (DME).

The company bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios in a deal worth up to $2 billion.

Shares of NantKwest were up more than 27% in premarket trading after the company announced a stock-for-stock reverse merger with privately-held ImmunityBio.

Myovant’s oral Orgovyx beat out Abbvie’s injectable Lupron in achieving medical castration levels in patients. Here is the timeline of the approval.

BioSkryb has developed a more robust technology for whole genome sequencing that accurately and uniformly captures more than 95% of the genomes of single cells.

A new and more easily transmissible strain of COVID-19, dubbed VUI-202012/01, has now been reported in at least six different countries and global territories since it first appeared in the U.K. a few weeks ago.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today announced new hire grants totaling an aggregate of 41,900 inducement restricted stock awards (“RSAs”) to 15 employees. The RSAs vest over four years, with 25% of the underlying shares vesting on each of t

The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity